dangers of glp-1 The Dangers of Using Unapproved

(28) The study included 1,222,436 patients with type 2 diabetes who were newly prescribed SGLT-2 inhibitors, GLP-1 agonists, DPP4-Is, or older antidiabetic agents (metformin, sulfonylureas, alpha glucosidase inhibitors, thiazolidinediones), with patients categorized based on their first recorded prescription

Patients who wish to continue treatment beyond their initial program duration would need to enroll in a new program cycle

Clinical trials show average outcomes of 15 to 21% body weight loss over 68 weeks depending on the medication, though individual results vary

Idiosyncratic drug reactions

Melatonin is a hormone directly involved in regulating sleep-wake cycles